The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1559
Cannabidiol (Epidiolex) for Epilepsy
The full article is available to subscribers Subscriber Login   

The FDA has approved cannabidiol oral solution (Epidiolex – Greenwich Biosciences) for treatment of seizures associated with Dravet syndrome or Lennox-Gastaut syndrome in patients ≥2 years old. Cannabidiol (CBD) is a cannabinoid constituent of the marijuana plant (Cannabis sativa). It is the first natural marijuana product to be approved by the FDA for any indication and the first drug to be approved in the US for treatment of Dravet syndrome. Stiripentol (Diacomit), which is not a marijuana product, was also recently approved by the FDA for treatment of Dravet syndrome in combination with clobazam (Onfi) and will be reviewed in a future issue.

STANDARD TREATMENT — Dravet syndrome is a rare form of epileptic encephalopathy. It is primarily caused by mutations in the voltage-gated sodium channel α1 subunit (SCN1A) gene and is characterized by seizure onset before the age of ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Cannabidiol (Epidiolex) for Epilepsy
Article code: 1559c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian